Argenica Therapeutics has assembled an internationally recognised stroke advisory panel as it prepares the Phase 2b clinical development pathway for
Dr Liz Dallimore, Managing Director of Argenica Therapeutics, explains why securing an EMA paediatric waiver for ARG-007 materially simplifies the
Argenica Therapeutics (ASX:AGN) clears a major regulatory hurdle with positive drug-drug interaction results for ARG-007, bringing the company closer to
Liz Dallimore says the independent MCAo data marks a pivotal confirmation of ARG 007’s neuroprotective activity and sharpens the company’s
Dr Liz Dallimore, says the company’s latest Phase 2 trial results for ARG-007 demonstrate encouraging trends in patient recovery and
Argenica Therapeutics (ASX:AGN) has released promising data from its Phase 2 clinical trial of ARG-007, a neuroprotective peptide designed to
Argenica Therapeutics may have cracked the code on treating brain injury, with a ferret study showing its lead drug ARG-007
Argenica Therapeutics has secured a new US patent that positions its lead drug, ARG-007, at the forefront of preventing stroke
Argenica Therapeutics’ ARG-007 has demonstrated compelling neuroprotective effects in preclinical models of traumatic brain injury, reducing brain cell damage and
Argenica Therapeutics (ASX:AGN) moves closer to a potential breakthrough in stroke treatment as its Phase 2 trial of ARG-007 nears
Argenica Therapeutics (ASX:AGN) has dosed 80% of patients in its Phase 2 trial for ARG-007, a promising stroke therapy, with
Argenica Therapeutics advances its stroke treatment with ARG-007, achieving a key safety milestone in its Phase 2 trial, signalling promising
